News Summary

Isomorphic Labs, a startup focused on using artificial intelligence for drug discovery, has successfully raised $600 million in its first external funding round. The funding was led by Thrive Capital, with participation from Google Ventures and Alphabet, who have previously supported the company. Isomorphic Labs, which originated as a spin-off from Google DeepMind, plans to utilize the funds to enhance research and development and expand its team. The London-based company, founded in 2021, is part of a growing trend of tech companies integrating AI-powered solutions into their operations.